Credit: Insilico Medicine
Wednesday, February 27, 2019 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the BIO Asia International Conference on March 6, 2019.
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in making the hunt for new pharmaceuticals quicker and more effective. The presentation will focus on how Artificial Intelligence demonstrates the potential to lower costs of R&D in pharmaceutical industry, helps to target patient populations more effectively, improves efficiency, and ultimately, brings new medicines to market more quickly.
“We feel privileged to present our work at the Bio Asia 2019 and elaborate on the topic of AI technology, data challenges and its incorporation in the business operations. The topic of AI for Drug Discovery is picking up rapidly, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area,” says Dr. Jimmy Yen-Chu Lin, Chief Scientific Officer of Insilico Taiwan.
The Annual BIO Asia is an exclusive, senior-level executives forum that brings together U.S. and European drug development companies with Asian state-of-art biotech and pharmaceutical companies together in one place at one time.
###
For further information, images or interviews, please contact:
Contact: Artur Katurin
[email protected]
Website: http://insilico.
BioAsia Official Website:
https:/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets, published on several seminal peer-reviewed papers. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Media Contact
Artur Kadurin
[email protected]
